CNE TECH CORP(00611): Wang Haoying appointed as Chairman of the Board
China Nuclear Energy Technology (00611) announced that Mr. Li Hongwei has resigned as Chairman of the Board of Directors, Executive Director, member of the company's Remuneration Committee, Chairman of the company's Nomination Committee, the company's authorized representative as defined under Rule 3.05 of the Listing Rules of The Stock Exchange of Hong Kong Limited, and the company's authorized representative for receiving legal process documents and notices in Hong Kong as required under Rule 19.05(2) of the Listing Rules and Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) due to work reassignment, all effective from January 27, 2026.
CNE TECH CORP (00611) announced that Mr. Li Hongwei has resigned from his position as Chairman of the Board, Executive Director, member of the Company Salary Committee, Chairman of the Company Nomination Committee, the Company's authorized representative as defined in Hong Kong Stock Exchange Listing Rules 3.05, and the authorized representative of the Company for receiving legal process documents and notices in Hong Kong as required by Listing Rule 19.05(2) and Section 16 of the Companies Ordinance (Chapter 622 of the Hong Kong statutes). These changes will be effective from January 27, 2026. Following Mr. Li's resignation and upon the recommendation of the Nomination Committee, Mr. Wang Haoying has been appointed as Chairman, Non-Executive Director, member of the Salary Committee, Chairman of the Nomination Committee, authorized representative and legal process agent, effective from January 27, 2026.
After Mr. Li's resignation, there have been changes in the members of the Board of Directors. Details are as follows: Mr. Li will no longer serve as a member of the Salary Committee and Chairman of the Nomination Committee, and Mr. Wang has been appointed as a member of the Salary Committee and Chairman of the Nomination Committee, effective from January 27, 2026.
Related Articles

Metallurgical Corporation of China (01618) repurchased a total of 7.6478 million shares on January 27th.

Jiangsu Hengrui Pharmaceuticals (01276): HRS-5346 tablets have been included in the list of breakthrough therapies by the drug approval center.

VITASOY INT'L (00345) spent HKD 847,900 on January 27 to repurchase 12,200 shares.
Metallurgical Corporation of China (01618) repurchased a total of 7.6478 million shares on January 27th.

Jiangsu Hengrui Pharmaceuticals (01276): HRS-5346 tablets have been included in the list of breakthrough therapies by the drug approval center.

VITASOY INT'L (00345) spent HKD 847,900 on January 27 to repurchase 12,200 shares.

RECOMMEND

New Record Achieved As Spot Gold Tops $5,000 For The First Time; Institutions Set $6,600 Target
27/01/2026

117 Companies Raised Over HKD 285.6 Billion Through IPOs As Hong Kong Reclaims Global Leadership In 2025
27/01/2026

“A+H Hong Kong Listing Requires RMB 30 Billion Market Cap”? On‑Site Inquiry Dispels The Rumor
27/01/2026


